OrPro Therapeutics is a San Diego-based preclinical-stage biotechnology company established in 2006. The company, a Johnson & Johnson JLABS alumni, is dedicated to addressing unmet medical needs in acute and chronic respiratory, ophthalmology, and oncology fields. OrPro Therapeutics utilizes a cell-protective biologic drug platform based on the secreted human protein thioredoxin. Its lead asset, ORP100S, has demonstrated efficacy in reducing inflammation, normalizing mucociliary functions, and mitigating adverse effects of chemotherapy and radiation on stem cells in bone marrow and other sensitive organs. The drug operates through a novel covalent-binding mechanism, presenting potential disease-modifying treatment opportunities in obstructive, oxidative and inflammatory disorders, vision-threatening diseases of the retina, and cancer therapy.
The latest notable investment in OrPro Therapeutics took place on 19th July 2022, with a $2.15M grant from the U.S. Department of Defense.
Overall, OrPro Therapeutics' pioneering approach to developing therapeutic solutions leveraging the human protein thioredoxin holds promise in addressing critical medical needs across multiple domains.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Grant | $2.15M | 1 | U.S. Department of Defense | 19 Jul 2022 |
| Series A | $2.34M | - | 17 Feb 2016 |
No recent news or press coverage available for Orpro Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
